| URL | https://bioprocessintl.com/bioprocess-insider/faci |
| Source | Bioprocess International |
| Date Published | 09/10/2020 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Catalent Cell & Gene Therapy |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2022 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 130 |
| City reshored to: | Harmans |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | gene therapy products |
| What domestic positive factors made reshoring more attractive? | Under-utilized capacity |